Logo image of NCNA

NUCANA PLC-ADR (NCNA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:NCNA - US67022C3043 - ADR

3.37 USD
-0.23 (-6.39%)
Last: 1/9/2026, 8:10:16 PM
3.42 USD
+0.05 (+1.48%)
After Hours: 1/9/2026, 8:10:16 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to NCNA. NCNA was compared to 530 industry peers in the Biotechnology industry. The financial health of NCNA is average, but there are quite some concerns on its profitability. NCNA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NCNA had negative earnings in the past year.
NCNA had a negative operating cash flow in the past year.
In the past 5 years NCNA always reported negative net income.
NCNA had a negative operating cash flow in each of the past 5 years.
NCNA Yearly Net Income VS EBIT VS OCF VS FCFNCNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

NCNA's Return On Assets of -85.16% is on the low side compared to the rest of the industry. NCNA is outperformed by 69.81% of its industry peers.
NCNA has a Return On Equity (-106.15%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -85.16%
ROE -106.15%
ROIC N/A
ROA(3y)-94.3%
ROA(5y)-72.74%
ROE(3y)-195.95%
ROE(5y)-136.12%
ROIC(3y)N/A
ROIC(5y)N/A
NCNA Yearly ROA, ROE, ROICNCNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NCNA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NCNA Yearly Profit, Operating, Gross MarginsNCNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

NCNA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, NCNA has more shares outstanding
Compared to 1 year ago, NCNA has an improved debt to assets ratio.
NCNA Yearly Shares OutstandingNCNA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M
NCNA Yearly Total Debt VS Total AssetsNCNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

An Altman-Z score of 87.82 indicates that NCNA is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 87.82, NCNA belongs to the best of the industry, outperforming 98.68% of the companies in the same industry.
NCNA has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.00, NCNA perfoms like the industry average, outperforming 49.25% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 87.82
ROIC/WACCN/A
WACCN/A
NCNA Yearly LT Debt VS Equity VS FCFNCNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

NCNA has a Current Ratio of 4.76. This indicates that NCNA is financially healthy and has no problem in meeting its short term obligations.
NCNA's Current ratio of 4.76 is in line compared to the rest of the industry. NCNA outperforms 55.47% of its industry peers.
A Quick Ratio of 4.76 indicates that NCNA has no problem at all paying its short term obligations.
NCNA has a Quick ratio (4.76) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.76
Quick Ratio 4.76
NCNA Yearly Current Assets VS Current LiabilitesNCNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 99.87% over the past year.
EPS 1Y (TTM)99.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, NCNA will show a small growth in Earnings Per Share. The EPS will grow by 2.20% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y34%
EPS Next 2Y37.55%
EPS Next 3Y20.95%
EPS Next 5Y2.2%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NCNA Yearly Revenue VS EstimatesNCNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2029 2030 2031 2032 50M 100M 150M
NCNA Yearly EPS VS EstimatesNCNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1K -2K -3K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

NCNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NCNA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NCNA Price Earnings VS Forward Price EarningsNCNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NCNA Per share dataNCNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60

4.3 Compensation for Growth

A more expensive valuation may be justified as NCNA's earnings are expected to grow with 20.95% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.55%
EPS Next 3Y20.95%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NCNA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

NUCANA PLC-ADR

NASDAQ:NCNA (1/9/2026, 8:10:16 PM)

After market: 3.42 +0.05 (+1.48%)

3.37

-0.23 (-6.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)03-18 2026-03-18/amc
Inst Owners2.48%
Inst Owner Change0%
Ins Owners0%
Ins Owner ChangeN/A
Market Cap1.29B
Revenue(TTM)N/A
Net Income(TTM)-27.52M
Analysts82.5
Price TargetN/A
Short Float %0.05%
Short Ratio1.69
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 36.91
P/tB 40.33
EV/EBITDA N/A
EPS(TTM)-68.8
EYN/A
EPS(NY)-1.64
Fwd EYN/A
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS0
BVpS0.09
TBVpS0.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -85.16%
ROE -106.15%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-94.3%
ROA(5y)-72.74%
ROE(3y)-195.95%
ROE(5y)-136.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 60.63%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.76
Quick Ratio 4.76
Altman-Z 87.82
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)70.01%
Cap/Depr(5y)101.29%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y34%
EPS Next 2Y37.55%
EPS Next 3Y20.95%
EPS Next 5Y2.2%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y35.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y58.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y58.45%
OCF growth 3YN/A
OCF growth 5YN/A

NUCANA PLC-ADR / NCNA FAQ

What is the ChartMill fundamental rating of NUCANA PLC-ADR (NCNA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to NCNA.


What is the valuation status of NUCANA PLC-ADR (NCNA) stock?

ChartMill assigns a valuation rating of 1 / 10 to NUCANA PLC-ADR (NCNA). This can be considered as Overvalued.


Can you provide the profitability details for NUCANA PLC-ADR?

NUCANA PLC-ADR (NCNA) has a profitability rating of 0 / 10.